Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells.

@article{Tibullo2013NuclearTO,
  title={Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells.},
  author={Daniele Tibullo and Ignazio Barbagallo and Cesarina Giallongo and Piera La Cava and Nunziatina Laura Parrinello and Luca Vanella and Fabio Stagno and Giuseppe Palumbo and Giovanni Li Volti and Francesco Di Raimondo},
  journal={Current pharmaceutical design},
  year={2013},
  volume={19 15},
  pages={
          2765-70
        }
}
Identification of imatinib mesylate as a potent inhibitor of the Abl kinase and the subsequent findings that this compound displays growth inhibitory and pro-apoptotic effects in Bcr-Abl+ cells, has deeply conditioned CML treatment. Unfortunately the initial striking efficacy of this drug has been overshadowed by the development of clinical resistance. A… CONTINUE READING